Clinical trial · Observational
Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer
Development of a Model to Predict Progression Free Survival After Treatment With Erlotinib in E3503
NCT00897533CI-TRIAL-00027708completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment with erlotinib. PURPOSE: This laboratory study is developing a model to predict progression-free survival after erlotinib in patients with non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diagnostic laboratory biomarker analysis | Other | — | UNRESOLVED |
| gene mapping | Genetic | — | UNRESOLVED |
| immunohistochemistry staining method | Other | — | UNRESOLVED |
| polymorphism analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Mesenchymal and epithelial markers
- timeFrame
- 1 month
- description
- Mesenchymal and epithelial markers
- measure
- Loss of epithelial markers (E-cadherin) and gain of mesenchymal markers (vimentin/cytokeratin co-expression)
- timeFrame
- 1 month
- description
- Loss of epithelial markers (E-cadherin) and gain of mesenchymal markers
- measure
- Correlation of progression-free survival (PFS) by mesenchymal and epithelial markers
- timeFrame
- 1 month
- description
- Correlation of progression-free survival (PFS) by mesenchymal and epithelial markers
- measure
- Identification of a single nucleotide polymorphism profile via whole genome mapping and other known biomarkers to predict PFS
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of non-small cell lung cancer, including any of the following subtypes: * Adenocarcinoma * Squamous cell carcinoma * Bronchoalveolar carcinoma * Carcinoid * Stage IIIB or IV or recurrent disease * Must have received treatment with erlotinib hydrochloride on clinical trial ECOG-E3503 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (1)
- RESULTAmann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP. Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol. 2010 Feb;5(2):169-78. doi: 10.1097/JTO.0b013e3181c8cbd9. PMID 20035238